THE 2-MINUTE RULE FOR MBL77

For patients with symptomatic disease demanding therapy, ibrutinib is usually suggested determined by 4 stage III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 as well as other usually employed CIT combos, specifically FCR, bendamustine as well as rituximab and chlorambucil furthermore obinutuzumab (ClbO).107–1